Language Selection

Get healthy now with MedBeds!
Click here to book your session

Protect your whole family with Orgo-Life® Quantum MedBed Energy Technology® devices.

Advertising by Adpathway

         

 Advertising by Adpathway

Nucleoporin 50 Reduces TDP-43 Aggregation in Cellular Models of ALS and FTD

2 days ago 2

PROTECT YOUR DNA WITH QUANTUM TECHNOLOGY

Orgo-Life the new way to the future

  Advertising by Adpathway

Expression of nucleoporin 50 acts as a protective modifier against TDP-43 proteinopathy in cellular models of amyotrophic lateral sclerosis and frontotemporal degeneration, according to findings published in Molecular Neurodegeneration. The study, led by Courtney L. Smith, Bilal Khalil, Wilfried Rossoll, and colleagues, demonstrates that increasing the levels of this nuclear pore component can directly alleviate several cellular hallmarks associated with neurodegenerative disease pathology.

In amyotrophic lateral sclerosis and frontotemporal degeneration, the nuclear depletion and abnormal cytoplasmic aggregation of the RNA-binding protein TDP-43 represent central neuropathological hallmarks. While previous scientific investigations have well documented widespread defects in nucleocytoplasmic transport within disease models and patient tissue, and established that nuclear transport receptors can modulate TDP-43 pathology, the functional role played by nucleoporins in TDP-43 mislocalization and aggregation has remained poorly understood.

To clarify this mechanism, the investigators tested the impact of nucleoporin 50, a protein previously linked genetically to amyotrophic lateral sclerosis risk, within cellular disease models. Their experimental observations revealed that nucleoporin 50 expression significantly reduces detergent-insoluble TDP-43, decreases visible TDP-43 aggregation, and suppresses pathological TDP-43 hyperphosphorylation. These measurements confirmed that elevated levels of the protein counteract core biochemical features of abnormal TDP-43 accumulation in cultured cells.

The research team subsequently examined the structural prerequisites underlying this protective effect, demonstrating that nucleoporin 50 activity against TDP-43 aggregation strictly depends on its physical association with the nuclear pore complex. Without interaction with the nuclear pore architecture, the protein fails to prevent the aberrant clustering of TDP-43, highlighting the necessity of proper pore complex localization for its protective modifier function.

Through molecular mapping, the authors succeeded in identifying a minimal 41-amino-acid fragment of nucleoporin 50 that retains the protective properties of the full-length molecule. This truncated sequence proved entirely sufficient both to maintain association with the nuclear pore complex and to mediate the reduction of pathological TDP-43 aggregation, narrowing the critical functional region of the nucleoporin down to a discrete, compact peptide domain.

The investigators then evaluated the biological efficacy of this minimal peptide sequence in primary neurons to determine whether the protective impact extended beyond non-neuronal cellular models. In these primary neuronal cultures, introduction of the active 41-amino-acid fragment substantially reduced TDP-43 aggregation while simultaneously mitigating neurotoxicity, establishing that this defined peptide domain can protect vulnerable neuronal cells against toxic pathological protein insults.

To examine the disease relevance of these observations, the researchers characterized an amyotrophic lateral sclerosis-linked nucleoporin 50 missense variant, discovering that it displayed impaired activity against TDP-43 aggregation. Furthermore, by examining post-mortem human brain tissue from affected donors, the team demonstrated that nucleoporin 50 partially co-localizes with pathological TDP-43 inclusions, connecting laboratory cellular phenotypes with physical pathological structures observed in clinical brain specimens.

Together, these findings identify nucleoporin 50 as a functional modifier of TDP-43 aggregation and toxicity, supporting an overarching model in which reduced nucleoporin 50 activity contributes directly to TDP-43 proteinopathy. While the current evidence is derived from cell culture systems, primary neurons, and post-mortem tissue rather than clinical patient trials, the authors highlight nucleoporin 50 activity and its 41-amino-acid active fragment as promising starting points for therapeutic development aimed at combating TDP-43 pathology.

Subject of Research: Nucleoporin 50 modulation of TDP-43 proteinopathy in ALS and FTD models

Article Title: Nucleoporin 50 rescues hallmarks of TDP-43 proteinopathy in ALS/FTD disease models

Article References: Smith, C. L., Khalil, B., Walker, A. C., Liu, F., Morderer, D., Morato, J. G., Hsieh, C., Altheim, C., Ghayal, N. B., Crook, R. J., White, A. E., Udine, E., Pottier, C., Vadakattu, P., Comyn, T., Lee, J. H., Ly, A. M., Raffelhueschen, A., Mason, E. G., … Rossoll, W. (2026). Nucleoporin 50 rescues hallmarks of TDP-43 proteinopathy in ALS/FTD disease models. Molecular Neurodegeneration. https://doi.org/10.1186/s13024-026-01001-8

Image Credits: AI Generated

DOI: 10.1186/s13024-026-01001-8

Keywords: nucleoporin 50, NUP50, TDP-43, proteinopathy, amyotrophic lateral sclerosis, frontotemporal degeneration, nuclear pore complex, nucleocytoplasmic transport, nuclear transport receptors, TDP-43 hyperphosphorylation, detergent-insoluble TDP-43, primary neurons, neurotoxicity, missense variant, human brain tissue, RNA-binding protein, pathological inclusions, minimal active fragment

Read Entire Article

         

        

Start the new Vibrations with a Medbed Franchise today!  

Protect your whole family with Quantum Orgo-Life® devices

  Advertising by Adpathway